These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 25273396)

  • 1. Induction of thyroid remission using rituximab in a patient with type 3 autoimmune polyglandular syndrome including Graves' disease and type 1 diabetes mellitus: a case report.
    Kurozumi A; Okada Y; Arao T; Narisawa M; Torimoto K; Yamamoto S; Tanaka Y
    Endocr J; 2015; 62(1):69-75. PubMed ID: 25273396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. B lymphocyte depletion with the monoclonal antibody rituximab in Graves' disease: a controlled pilot study.
    El Fassi D; Nielsen CH; Bonnema SJ; Hasselbalch HC; Hegedüs L
    J Clin Endocrinol Metab; 2007 May; 92(5):1769-72. PubMed ID: 17284622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New immunomodulators in the treatment of Graves' ophthalmopathy.
    Salvi M; Vannucchi G; Campi I; Currò N; Beck-Peccoz P
    Ann Endocrinol (Paris); 2008 Apr; 69(2):153-6. PubMed ID: 18417090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Graves' disease and associated ophthalmopathy with the anti-CD20 monoclonal antibody rituximab: an open study.
    Salvi M; Vannucchi G; Campi I; Currò N; Dazzi D; Simonetta S; Bonara P; Rossi S; Sina C; Guastella C; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2007 Jan; 156(1):33-40. PubMed ID: 17218723
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of rituximab treatment for thyroid-associated ophthalmopathy as a result of intraorbital B-cell depletion in one patient unresponsive to steroid immunosuppression.
    Salvi M; Vannucchi G; Campi I; Rossi S; Bonara P; Sbrozzi F; Guastella C; Avignone S; Pirola G; Ratiglia R; Beck-Peccoz P
    Eur J Endocrinol; 2006 Apr; 154(4):511-7. PubMed ID: 16556712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Novel treatment of Graves' disease using the B-lymphocyte depleting agent rituximab].
    Nielsen CH; El Fassi D; Hegedüs L
    Ugeskr Laeger; 2008 Jun; 170(24):2131-4. PubMed ID: 18565295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies of thyroid function and immune parameters in patients with hyperthyroid Graves' disease in remission.
    Murakami M; Koizumi Y; Aizawa T; Yamada T; Takahashi Y; Watanabe T; Kamoi K
    J Clin Endocrinol Metab; 1988 Jan; 66(1):103-8. PubMed ID: 3121661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Graves' disease with rituximab specifically reduces the production of thyroid stimulating autoantibodies.
    El Fassi D; Banga JP; Gilbert JA; Padoa C; Hegedüs L; Nielsen CH
    Clin Immunol; 2009 Mar; 130(3):252-8. PubMed ID: 18964302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential utility of rituximab for Graves' orbitopathy.
    Salvi M; Vannucchi G; Beck-Peccoz P
    J Clin Endocrinol Metab; 2013 Nov; 98(11):4291-9. PubMed ID: 24009135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.
    Vannucchi G; Campi I; Bonomi M; Covelli D; Dazzi D; Currò N; Simonetta S; Bonara P; Persani L; Guastella C; Wall J; Beck-Peccoz P; Salvi M
    Clin Exp Immunol; 2010 Sep; 161(3):436-43. PubMed ID: 20529087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune polyglandular syndrome type 3 variant in rheumatoid arthritis.
    Horino T; Ogasawara M; Ichii O; Terada Y
    Rom J Intern Med; 2020 Mar; 58(1):40-43. PubMed ID: 31756165
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab as Maintenance Therapy in Type 1 Autoimmune Pancreatitis: An Italian Experience.
    De Marchi G; de Pretis N; Gabrieletto EM; Amodio A; Davì V; Crinò SF; Gabbrielli A; Ciccocioppo R; Frulloni L
    Pancreas; 2021 Nov-Dec 01; 50(10):1363-1367. PubMed ID: 35041334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
    Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
    Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility alleles and haplotypes of human leukocyte antigen DRB1, DQA1, and DQB1 in autoimmune polyglandular syndrome type III in Japanese population.
    Hashimoto K; Maruyama H; Nishiyama M; Asaba K; Ikeda Y; Takao T; Iwasaki Y; Kumon Y; Suehiro T; Tanimoto N; Mizobuchi M; Nakamura T
    Horm Res; 2005; 64(5):253-60. PubMed ID: 16254435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.
    Bonara P; Vannucchi G; Campi I; Rossi S; Cantoni F; Frugoni C; Sbrozzi F; Guastella C; Avignone S; Beck-Peccoz P; Salvi M
    Clin Rev Allergy Immunol; 2008 Feb; 34(1):118-23. PubMed ID: 18270865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune polyglandular syndrome type II with co-manifestation of Addison's and Graves' disease in a 15-year-old boy: case report and literature review.
    Schulz L; Hammer E
    J Pediatr Endocrinol Metab; 2020 Apr; 33(4):575-578. PubMed ID: 32112702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A TSHR-LH/CGR chimera that measures functional thyroid-stimulating autoantibodies (TSAb) can predict remission or recurrence in Graves' patients undergoing antithyroid drug (ATD) treatment.
    Giuliani C; Cerrone D; Harii N; Thornton M; Kohn LD; Dagia NM; Bucci I; Carpentieri M; Di Nenno B; Di Blasio A; Vitti P; Monaco F; Napolitano G
    J Clin Endocrinol Metab; 2012 Jul; 97(7):E1080-7. PubMed ID: 22492869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polyserositis as a rare component of polyglandular autoimmune syndrome type II.
    Algün E; Erkoç R; Kotan C; Güler N; Sahin I; Ayakta H; Uygan I; Dilek I; Aksoy H
    Int J Clin Pract; 2001 May; 55(4):280-1. PubMed ID: 11406917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Persistent remission of Graves` disease or evolution from Graves' disease to Hashimoto's thyroiditis in childhood - a report of 6 cases and clinical implications.
    Smyczńyska J; Cyniak-Magierska A; Stasiak M; Karbownik-Lewińska M; Lewiński A
    Neuro Endocrinol Lett; 2014; 35(5):335-41. PubMed ID: 25275265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.